Johnson & Johnson (NYSE:JNJ) Shares Sold by Marcum Wealth LLC

Marcum Wealth LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 9,973 shares of the company’s stock after selling 696 shares during the period. Marcum Wealth LLC’s holdings in Johnson & Johnson were worth $1,442,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. One Capital Management LLC raised its position in shares of Johnson & Johnson by 22.2% during the 2nd quarter. One Capital Management LLC now owns 66,330 shares of the company’s stock worth $9,695,000 after buying an additional 12,034 shares in the last quarter. Citizens Financial Group Inc. RI raised its position in shares of Johnson & Johnson by 82.8% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 180,501 shares of the company’s stock worth $26,382,000 after buying an additional 81,780 shares in the last quarter. Wulff Hansen & CO. raised its position in shares of Johnson & Johnson by 14,424.6% during the 2nd quarter. Wulff Hansen & CO. now owns 1,625,299 shares of the company’s stock worth $237,554,000 after buying an additional 1,614,109 shares in the last quarter. Luts & Greenleigh Group Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $1,131,000. Finally, Excalibur Management Corp raised its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Excalibur Management Corp now owns 40,514 shares of the company’s stock worth $5,921,000 after purchasing an additional 629 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $144.68 on Wednesday. The company’s 50 day moving average price is $149.12 and its 200 day moving average price is $156.09. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a market capitalization of $348.33 billion, a PE ratio of 20.94, a PEG ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the firm posted $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 71.78%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JNJ. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.